SCHEMBL2382865

SCHEMBL2382865

CC(C)(O)c1cc(-c2cc(Cl)ccn2)cs1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.36
HSD17B1 P14061 2/20 0.35
HSD17B2 P37059 2/20 0.35
CNR2 P34972 2/20 0.34
MAP4K4 O95819 1/20 0.34
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GABRA1 P14867 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 1/20 0.33
FYN P06241 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
CNR1 P21554 1/20 0.32
CYP19A1 P11511 1/20 0.31
KDM4C Q9H3R0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382655 0.74 PIM1 (0.38) PIM1HSD17B1HSD17B2MAP4K4MAPT
SCHEMBL2384472 0.74 PIM1 (0.38) PIM1HSD17B1HSD17B2MAP4K4ALDH1A1
SCHEMBL2385102 0.73 KDM4C (0.37) PIM1HSD17B1HSD17B2MAP4K4ALDH1A1
SCHEMBL2385156 0.73 ALAD (0.42) PIM1MAP4K4ALDH1A1MAPTL3MBTL1
SCHEMBL24037300 0.71 HRH4 (0.36) HSD17B1HSD17B2CCR1CCR5CCR8
SCHEMBL9201801 0.70 MAPT (0.38) PIM1HSD17B1HSD17B2CNR2MAP4K4
SCHEMBL31312595 0.68 KIF11 (0.46) PIM1MAP4K4ALDH1A1MAPTPTGS1
SCHEMBL15263671 0.68 KIF11 (0.46) PIM1MAP4K4ALDH1A1MAPTPTGS1
SCHEMBL24037301 0.67 COMT (0.36) HSD17B1HSD17B2ALDH1A1MAPTCYP19A1
SCHEMBL827247 0.67 CCR1 (0.48) PIM1ALDH1A1MAPTL3MBTL1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022209-B2 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-09-20 US disclosed
WO-2009035671-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 WO disclosed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor HRH4, HRH3, HRH2 PIM1 4865/4885HSD17B1 4486/4885HSD17B2 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.